Physiology and pathophysiology of iron cardiomyopathy in thalassemia

Annals of the New York Academy of Sciences

Volumn 1054, Issue , 2005, Pages 386-395

  Wood, John C ^a   Enriquez, Cathleen ^a   Ghugre, Nilesh ^a   Otto Duessel, Maya ^a   Aguilar, Michelle ^a   Nelson, Marvin D ^a   Moats, Rex ^a   Coates, Thomas D ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Cardiac function; Ejection fraction; Heart; Iron; MRI; T2*

Indexed keywords

IRON;

ANEMIA; BLOOD TRANSFUSION; BODY BURDEN; CARDIOMYOPATHY; CAUSE OF DEATH; CONFERENCE PAPER; EARLY DIAGNOSIS; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART OUTPUT; HEART VENTRICLE SIZE; HEART VENTRICLE VOLUME; HEMODYNAMIC MONITORING; HUMAN; IRON CARDIOMYOPATHY; IRON OVERLOAD; IRON STORAGE; LIVER LEVEL; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT MONITORING; PHYSIOLOGY; RISK ASSESSMENT; THALASSEMIA; THALASSEMIA MAJOR; VASCULAR RESISTANCE;

EID: 29744455463     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1345.047     Document Type: Conference Paper

References (44)

1. WEATHERALL, D.J. 1998. Thalassemia in the next millennium. Keynote address. Ann. N.Y. Acad. Sci. 850: 1-9.
2. BORGNA-PIGNATTI, C., S. RUGOLOTTO, P. DE STEFANO, et al. 2004. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89: 1187-1193.
3. ALDOURI, M.A., B. WONKE, A.V. HOFFBRAND, et al. 1990. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol. 84: 113-117.
4. VECCHIO, C. & G. DERCHI. 1995. Management of cardiac complications in patients with thalassemia major. Semin. Hematol. 32: 288-296.
5. DAVIS, B.A., C. O'SULLIVAN, P.H. JARRITT & J.B. PORTER. 2004. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 104: 263-269.
6. DAVIS, B.A. & J.B. PORTER. 2000. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 95: 1229-1236.
7. GHARZUDDINE, W.S., H.K. KAZMA, I.A. NUWAYHID, et al. 2002. Doppler characterization of left ventricular diastolic function in beta-thalassaemia major. Evidence for an early stage of impaired relaxation. Eur. J. Echocardiogr. 3: 47-51.
8. KREMASTINOS, D.T., D.P. TSIAPRAS, G.A. TSETSOS, et al. 1993. Left ventricular diastolic Doppler characteristics in beta-thalassemia major. Circulation 88: 1127-1135.
9. AESSOPOS, A., D. FARMAKIS, A. HATZILIAMI, et al. 2004. Cardiac status in well-treated patients with thalassemia major. Eur. J. Haematol. 73: 359-366.
10. WOOD, J.C., T.M. TYSZKA, N. GHUGRE, et al. 2004. Myocardial iron loading in transfusion-dependent thalassemia and sickle-cell disease. Blood 103: 1934-1936.
11. LORENZ, C.H., E.S. WALKER, V.L. MORGAN, et al. 1999. Normal human right and left ventricular mass, systolic function, and gender differences by cine magnetic resonance imaging. J. Cardiovasc. Magn. Reson. 1: 7-21.
12. BRITTENHAM, G.M., P.M. GRIFFITH, A.W. NIENHUIS, et al. 1994. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N. Engl. J. Med. 331: 567-573.
13. VOSKARIDOU, E., M. DOUSKOU, E. TERPOS, et al. 2004. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br. J. Haematol. 126: 736-742.
14. WOOD, J.C., N. GHUGRE, S. CARSON, et al. 2003. Predictors of abnormal myocardial function and T2* in children and young adults with thalassemia major. Blood 102: 952a.
15. ANDERSON, L.J., S. HOLDEN, B. DAVIS, et al. 2001. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur. Heart J. 22: 2171-2179.
16. WESTWOOD, M.A., L.J. ANDERSON, M.A. TANNER & D.J. PENNELL. 2005. The relationship between myocardial iron deposition and left ventricular dysfunction in thalassemia using cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 7: 46-47.
17. OLIVIERI, N.F. & G.M. BRITTENHAM. 1997. Iron-chelating therapy and the treatment of thalassemia. Blood 89: 739-761.
18. WOOD, J.C., M. OTTO-DUESSEL, M. AGUILAR, et al. 2005. Cardiac MRI (T2, T2*) predicts cardiac iron in the gerbil model of iron cardiomyopathy. Circulation 112: 535-543.
19. WANG, Z.J., L. LIAN, Q. CHEN, et al. 2005. 1/T2 and magnetic susceptibility measurements in a gerbil cardiac iron overload model. Radiology 234: 749-755.
20. 3+ transport by iron-loaded cardiac myocytes. Toxicology 117: 141-151.
21. LIU, Y., J.G. PARKES & D.M. TEMPLETON. 2003. Differential accumulation of non-transferrin-bound iron by cardiac myocytes and fibroblasts. J. Mol. Cell. Cardiol. 35: 505-514.
22. PARKES, J.G., R.A. HUSSAIN, N.F. OLIVIERI & D.M. TEMPLETON. 1993. Effects of iron loading on uptake, speciation, and chelation of iron in cultured myocardial cells. J. Lab. Clin. Med. 122: 36-47.
23. 2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat. Med. 9: 1187-1194.
24. RANDELL, E.W., J.G. PARKES, N.F. OLIVIERI & D.M. TEMPLETON. 1994. Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron. J. Biol. Chem. 269: 16046-16053.
25. JENSEN, P.D., F.T. JENSEN, T. CHRISTENSEN, et al. 2003. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 101: 4632-4639.
26. BUJA, L.M. & W.C. ROBERTS. 1971. Iron in the heart. Etiology and clinical significance. Am. J. Med. 51: 209-221.
27. ESPOSITO, B.P., W. BREUER, P. SIRANKAPRACHA, et al. 2003. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102: 2670-2677.
28. SHILOH, H., T.C. IANCU, E.R. BAUMINGER, et al. 1992. Deferoxamine-induced iron mobilization and redistribution of myocardial iron in cultured rat heart cells: studies of the chelatable iron pool by electron microscopy and Mossbauer spectroscopy. J. Lab. Clin. Med. 119: 428-436.
29. STUHNE-SEKALEC, L., S.X. XU, J.G. PARKES, et al. 1992. Speciation of tissue and cellular iron with on-line detection by inductively coupled plasma-mass spectrometry. Anal. Biochem. 205: 278-284.
30. IANCU, T.C., H. SHILOH, G. LINK, et al. 1987. Ultrastructural pathology of iron-loaded rat myocardial cells in culture. Br. J. Exp. Pathol. 68: 53-65.
31. WOOD, J.C., J. FASSLER & T. MEADE. 2004. Mimicking liver iron overload using liposomal ferritin preparations. Magn. Reson. Med. 51: 607-611.
32. LINK, G., A. PINSON & C. HERSHKO. 1993. Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. J. Lab. Clin. Med. 121: 127-134.
33. PARKES, J.G., Y. LIU, J.B. SIRNA & D.M. TEMPLETON. 2000. Changes in gene expression with iron loading and chelation in cardiac myocytes and non-myocytic fibroblasts. J. Mol. Cell. Cardiol. 32: 233-246.
34. KIM, E., S.N. GIRI & I.N. PESSAH. 1995. Iron(II) is a modulator of ryanodine-sensitive calcium channels of cardiac muscle sarcoplasmic reticulum. Toxicol. Appl. Pharmacol. 130: 57-66.
35. LINK, G., P. ATHIAS, A. GRYNBERG, et al. 1989. Effect of iron loading on transmembrane potential, contraction, and automaticity of rat ventricular muscle cells in culture. J. Lab. Clin. Med. 113: 103-111.
36. KURYSHEV, Y.A., G.M. BRITTENHAM, H. FUJIOKA, et al. 1999. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Implications for the arrhythmogenesis of human siderotic heart disease. Circulation 100: 675-683.
37. SELDEN, C., M. OWEN, J.M. HOPKINS & T.J. PETERS. 1980. Studies on the concentration and intracellular localization of iron proteins in liver biopsy specimens from patients with iron overload with special reference to their role in lysosomal disruption. Br. J. Haematol. 44: 593-603.
38. LINK, G., A. SAADA, A. PINSON, et al. 1998. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. J. Lab. Clin. Med. 131: 466-474.
39. RUSSELL, L.K., B.N. FINCK & D.P. KELLY. 2005. Mouse models of mitochondrial dysfunction and heart failure. J. Mol. Cell. Cardiol. 38: 81-91.
40. LIU, Y. & D.M. TEMPLETON. 2001. The effects of cardiac myocytes on interstitial fibroblasts in toxic iron overload. Cardiovasc. Toxicol. 1: 299-308.
41. LAURITA, K.R., E.T. CHUCK, T. YANG, et al. 2003. Optical mapping reveals conduction slowing and impulse block in iron-overload cardiomyopathy. J. Lab. Clin. Med. 142: 83-89.
42. POGWIZD, S.M. & D.M. BERS. 2004. Cellular basis of triggered arrhythmias in heart failure. Trends Cardiovasc. Med. 14: 61-66.
43. ANDERSON, L.J., M.A. WESTWOOD, S. HOLDEN, et al. 2004. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br. J. Haematol. 127: 348-355.
44. MARIOTTI, E., E. ANGELUCCI, A. AGOSTINI, et al. 1998. Evaluation of cardiac status in iron loaded thalassemia patients following bone marrow transplantation during reduction in body iron burden. Br. J. Haematol. 103: 916-921.